What are the most concerning consequences of the drug and other weight-loss medicines? - Gastrointestinal and cardiovascular ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently diagnosed with Parkinson’s Disease ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

Canada's new obesity guidelines signal a shift in food consumption, with GLP-1 drugs impacting how and what Canadians—especially youth—eat.

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and cardiovascular health has significant implications for orthopedic surgery.GLP-1 ...